Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Axsome Therapeutics (AXSM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$125.31 | $190.00 | $95.00 | 45.74% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for Axsome Therapeutics comes to $125.31. The forecasts range from a low of $95.00 to a high of $190.00. The average price target represents an increase of 45.74% from the last closing price of $85.98.
Analyst Price Targets (16)
Broker Rating
Axsome Therapeutics currently has an average brokerage recommendation (ABR) of 1.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.19 a month ago based on 16 recommendations.
Of the 17 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 82.35% and 11.76% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 6.25%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AXSM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 14 | 14 | 14 |
Buy | 2 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.24 | 1.19 | 1.19 | 1.19 | 1.19 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
7/22/2024 | Needham & Company | Ami Fadia | Not Available | Moderate Buy |
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/6/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
5/6/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
5/6/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
5/6/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/28/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
3/26/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
3/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/19/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Strong Buy |
2/21/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
2/6/2024 | UBS | Ashwani Verma | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.24 |
ABR (Last week) | 1.19 |
# of Recs in ABR | 17 |
Average Target Price | $125.31 |
LT Growth Rate | 38.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -1.30 |